CoChat

HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival

Open access

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Abstract

Over the past four decades there have been minimal improvements in outcomes for patients with osteosarcoma. New targets and novel therapies are needed to improve outcomes for these patients. We sought to evaluate the prevalence and clinical significance of the newest immune checkpoint, HHLA2, in osteosarcoma. HHLA2 protein expression was evaluated in primary tumor specimens and metastatic disease using an osteosarcoma tumor microarray (TMA) (n = 62). The association of HHLA2 with the presence of tumor infiltrating lymphocytes (TILs) and five-year-event-free-survival were examined. HHLA2 was expressed in 68% of osteosarcoma tumors. HHLA2 was expressed in almost all metastatic disease specimens and was more prevalent than in primary specimens without known metastases (93% vs 53%, p = 0.02). TILs were present in 75% of all osteosarcoma specimens. Patients whose tumors were ≥25% or ≥50% HHLA2 positive had significantly worse five-year event-free-survival (33% vs 64%, p = 0.03 and 14% vs 59%, p = 0.02). Overall, we have shown that HHLA2 is expressed in the majority of osteosarcoma tumors and its expression is associated with metastatic disease and poorer survival. Along with previously reported findings that HHLA2 is a T cell co-inhibitor, these results suggest that HHLA2 may be a novel immunosuppressive mechanism within the osteosarcoma tumor microenvironment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep31154

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 HHLA2 is expressed in the majority of osteosarcoma tumors. (A) representative tumors for each HHLA2 grade based on IHC. The ICH scores were based on the percentage of tumor cells that were HHHLA2 positive, with the five subdivisions being: negative, less than 25% positive, 25% ≤ HHLA2 < 50%, 51% ≤ HHLA2 < 75%, and equal or greater than 75% positive. Scale bar, 100 μM. (B) The majority of tumors examined were HHLA2 positive at all times of diseases progression. There is a significant decrease in HHLA2 positive cells between the time of biopsy and definitive surgery (77% vs 53%, p = 0.03). Metastatic samples have a higher percentage of cells staining positive for HHLA2 when compared to samples at definitive surgery (93% vs 53%, p = 0.01) and at biopsy (93% vs 77%, p = 0.001). (C) HHLA2 expression was sorted into three groups based on tissue type and presence of metastasis: primary tissue with metastasis, primary tissue without metastasis, and metastatic tissue. The percentage of cells expressing HHLA2 is significantly increased in metastatic tissue compared to primary tissue without presence of metastatic disease (53% vs 93%, p = 0.02).
Figure 1 HHLA2 is expressed in the majority of osteosarcoma tumors. (A) representative tumors for each HHLA2 grade based on IHC. The ICH scores were based on the percentage of tumor cells that were HHHLA2 positive, with the five subdivisions being: negative, less than 25% positive, 25% ≤ HHLA2 < 50%, 51% ≤ HHLA2 < 75%, and equal or greater than 75% positive. Scale bar, 100 μM. (B) The majority of tumors examined were HHLA2 positive at all times of diseases progression. There is a significant decrease in HHLA2 positive cells between the time of biopsy and definitive surgery (77% vs 53%, p = 0.03). Metastatic samples have a higher percentage of cells staining positive for HHLA2 when compared to samples at definitive surgery (93% vs 53%, p = 0.01) and at biopsy (93% vs 77%, p = 0.001). (C) HHLA2 expression was sorted into three groups based on tissue type and presence of metastasis: primary tissue with metastasis, primary tissue without metastasis, and metastatic tissue. The percentage of cells expressing HHLA2 is significantly increased in metastatic tissue compared to primary tissue without presence of metastatic disease (53% vs 93%, p = 0.02).CC BY · PubMed Central
Figure 2 TILs are present in the majority of osteosarcoma tumors. (A) H&E staining was used to assess the presence of TILs in osteosarcoma samples. Samples were graded as having no TILs, low TILs (<30% TILs), or high TILs (>30% TILs). Scale bar, 100 μM. (B) TILs are present in the majority of osteosarcoma samples at all times of specimen collection. (C) TILs are present at high levels in osteosarcoma regardless of the HHLA2 status.
Figure 2 TILs are present in the majority of osteosarcoma tumors. (A) H&E staining was used to assess the presence of TILs in osteosarcoma samples. Samples were graded as having no TILs, low TILs (<30% TILs), or high TILs (>30% TILs). Scale bar, 100 μM. (B) TILs are present in the majority of osteosarcoma samples at all times of specimen collection. (C) TILs are present at high levels in osteosarcoma regardless of the HHLA2 status.CC BY · PubMed Central
Figure 3 The majority of HHLA2 expression is on the tumor. (A) OS1 tumor demonstrated HHLA2 expression in a small area of the tumor. CD45 positive myeloid cells, which were clearly HHLA2 negative, were present. (B) OS2 tumor demonstrated HHLA2 expression homogenously throughout the tumor. CD45 positive myeloid cells, some of which were HHLA2 positive, were present. (C) Kidney tissue demonstrated HHLA2 expression in the renal tubules. Of the CD45 positive myeloid cells present, a small fraction were also HHLA2 positive. (D) Brain tissue was negative for both HHLA2 expression and CD45 myeloid cell infiltration.
Figure 3 The majority of HHLA2 expression is on the tumor. (A) OS1 tumor demonstrated HHLA2 expression in a small area of the tumor. CD45 positive myeloid cells, which were clearly HHLA2 negative, were present. (B) OS2 tumor demonstrated HHLA2 expression homogenously throughout the tumor. CD45 positive myeloid cells, some of which were HHLA2 positive, were present. (C) Kidney tissue demonstrated HHLA2 expression in the renal tubules. Of the CD45 positive myeloid cells present, a small fraction were also HHLA2 positive. (D) Brain tissue was negative for both HHLA2 expression and CD45 myeloid cell infiltration.CC BY · PubMed Central
Figure 4 Higher percentages of HHLA2 expressing tumor cells are associated with worse survival in osteosarcoma. Kaplan-Meyer curves were generated using multiple HHLA2 positive thresholds–specifically all HHLA2 positive, greater than 26% HHLA2 positive, and greater than 51% HHLA2 positive. (A) HHLA2 does not appear to be significantly associated with 5-year event free survival (5-yr EPS) when the positive threshold is set to ‘greater than zero’ (50% positive vs 61% negative, p = 0.45). (B,C) When the thresholds for positivity are set higher there are significantly worse 5-yr EPS for patients whose tumors are greater than 25% (64% vs 33%, p = 0.03) or 51% HHLA2 positive (59% vs 14%, p = 0.02) vs those that are not.
Figure 4 Higher percentages of HHLA2 expressing tumor cells are associated with worse survival in osteosarcoma. Kaplan-Meyer curves were generated using multiple HHLA2 positive thresholds–specifically all HHLA2 positive, greater than 26% HHLA2 positive, and greater than 51% HHLA2 positive. (A) HHLA2 does not appear to be significantly associated with 5-year event free survival (5-yr EPS) when the positive threshold is set to ‘greater than zero’ (50% positive vs 61% negative, p = 0.45). (B,C) When the thresholds for positivity are set higher there are significantly worse 5-yr EPS for patients whose tumors are greater than 25% (64% vs 33%, p = 0.03) or 51% HHLA2 positive (59% vs 14%, p = 0.02) vs those that are not.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Shen J. K. et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2, 690– 698, doi: 10.1158/2326-6066.CIR-13-0224 (2014). 24866169 PMC4082476 · DOI · Paper page

Cited by

See all 100

Metadata

Authors
Koirala, P., Roth, M. E., Gill, J., Chinai, J. M., Ewart, M. R., Piperdi, S., Geller, D. S., Hoang, B. H., Fatakhova, Y. V., Ghorpade, M., Zang, X., & Gorlick, R.
Affiliations
Albert Einstein College of Medicine (US)
Corresponding author
  • Zang, Xingxing
  • Gorlick, Richard
Venue
Scientific Reports
Published
2016-08-17
Volume
6
Issue
1
Pages
31154-31154
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2517687042
Cited by
100
References
34
Citations by year
2026: 3 · 2025: 8 · 2024: 16 · 2023: 14 · 2022: 11 · 2021: 15 · 2020: 9 · 2019: 12 · 2018: 7 · 2017: 4 · 2016: 1
FWCI
7.15
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Defense (PC131008)
  • Swim Across America
  • National Institutes of Health (5k12ca132783-12, 1s10od019961-01)
  • National Cancer Institute (K12-CA132783, R01CA175495)
  • National Institute of General Medical Sciences (T32GM007288)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK100525)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Keywords
HHLA2, B7 family, osteosarcoma, immune checkpoint, metastasis, tumor-infiltrating lymphocytes, event-free survival, tumor microenvironment, immunosuppression, T cell co-inhibition
MeSH terms
Adolescent, Adult, Bone Neoplasms, Child, Female, Humans, Immunoglobulins, Male, Prognosis, Osteosarcoma, Biomarkers, Tumor, Lymphocytes, Tumor-Infiltrating, Disease-Free Survival, Protein Array Analysis, Kaplan-Meier Estimate, Young Adult, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.